12 Drug DiScovery & DeveLopmenT
The outsourcing boom grows
for non-core pharma activities
here’s nothing like a darkening Many companies have already been tightening
There’s no competitive
economic climate and rising their operations around core activities such as
advantage in submissions
competitive pressures to focus a R&D and marketing, relying on outside vendors to
management, so why Tbusiness’s priorities. Like their handle non-core activities such as clinical trials.
be dragged down by
counterparts in other commercial sectors,
the process, asks Adam
pharmaceutical organisations are being forced to
The submissions burden
Sherlock. Let someone
re-examine their core and non-core activities to The onerous burden of licence submissions
else do it ...
determine where new efficiencies can be found, is now going this way too. Growing adoption
and to drive greater productivity and competitive of electronic submissions, particularly eCTD-
La gestion des demandes
agility into their operations. compliant submissions (based on the electronic
d’autorisation n’apporte
This is leading to a surge of interest in Common Technical Document standard)
aucun avantage outsourcing of non-core activities, as pharma means that managing all of the content and
concurrentiel, alors organisations attempt to sharpen their practices documentation has become a substantial
pourquoi se laisser
and reduce time to market. job. This is especially true in Europe, where
envahir par ce processus,
There are other challenges they need publishing requirements vary from one country to
s’interroge Adam
to address, too. The era of the blockbuster the next.
Sherlock. Laissons
quelqu’un d’autre le
drug is over, competition from generic As a result, there is now a growing interest in
faire…
drug manufacturers is increasing, and drug managed services, where an external specialist is
development pipelines are slowing. enlisted to take over non-core activities, freeing
Pharma organisations needs to respond by up skills internally. Fortuitously, this growth
Die eigene Abwicklung re-evaluating and streamlining their business in demand has coincided with an increasing
von Ausschreibungen
processes, removing redundancy and repetition availability of specialist managed services.
bringt keine
to enhance efficiency and reduce internal costs, ‘Strategic sourcing’ is proving particularly
Wettbewerbsvorteile.
so that they can move more deftly and exploit popular. This is a more flexible form of
Warum also sollte man
opportunities more cost-effectively. outsourcing, which draws on the most
sich davon lähmen lassen,
fragt Adam Sherlock.
appropriate combination of offshore, onshore,
Breaking old habits
Überlassen Sie es doch
and onsite resources.
lieber anderen ...
This is easier said than done, however. This is It offers pharma organisations substantial
an industry where habits and legacy processes cost benefits (derived from the service provider’s
are ingrained and there is a
resistance to change.
Yet, for many,
particularly those worried
about their agility and
long-term competitive
edge, or caught up in the
complexities of mergers and
acquisitions, it is clear that
something must be done
to make their operations
slicker.
As part of this
re-evaluation process,
organisations are being
forced to go back to basics
and to differentiate between
value-added business
processes and non-core
administrative activities that Fig. 1. Re-evaluation involves differentiating between value-added
drain time and resources business processes and non-core administrative activities that drain
(Fig. 1). time and resources.
www.scientistlive.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44